Share This

PR Newswire Asia's news

 |   Detail   |   Print    Next page > 
     
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
2024-06-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
2024-06-01T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
2024-06-01T    Health Care/Hospital   Medical/Pharmaceuticals 
Duke-NUS' largest graduating cohort celebrates diverse pathways to medicine
2024-06-01T    Education   Health Care/Hospital   Higher Education 
ZEEKR Announces May 2024 Delivery Update
2024-06-01T    Auto   Transportation 
BLUETTI EP760 Achieves CEC Approval, Enhancing Its Appeal in Australia
2024-06-01T    Alternative Energies   Environmental Products & Services   Green Technology 
Gold Pecker Leads the Way: First Expert Advisor to Offer 'PAMM by Gold Pecker' for Gold Traders
2024-06-01T    Banking/Financial Service   Computer/Electronics 
KED INVESTOR ALERT: Kaskela Law LLC Announces Investigation of Keypath Education International, Inc. (ASX: KED) and Encourages Investors to Contact the Firm
2024-06-01T  
MingZhu Logistics Agrees to Acquire Oxylus Global; Company Targeting Continued Aggressive Diversification and Growth Acceleration Strategy
2024-06-01T    Auto   Computer/Electronics   Transportation 
Hard Rock International Reignites "LOVE OUT LOUD" Pride Month 2024 Celebration with Special Events, Hotel Suites, Music Experiences, Cocktails and Merch
2024-06-01T    Entertainment   Hotels and Resorts   Travel 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.